摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 1-(4-cyano-2,6-dimethylphenethyl)piperidine-4-carboxylate | 1233500-62-3

中文名称
——
中文别名
——
英文名称
ethyl 1-(4-cyano-2,6-dimethylphenethyl)piperidine-4-carboxylate
英文别名
Ethyl 1-[2-(4-cyano-2,6-dimethylphenyl)ethyl]piperidine-4-carboxylate
ethyl 1-(4-cyano-2,6-dimethylphenethyl)piperidine-4-carboxylate化学式
CAS
1233500-62-3
化学式
C19H26N2O2
mdl
——
分子量
314.428
InChiKey
FVRXRJGJKWRJDG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    53.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 1-(4-cyano-2,6-dimethylphenethyl)piperidine-4-carboxylate盐酸羟胺三乙胺 作用下, 以 甲醇 为溶剂, 以80%的产率得到ethyl 1-(4-(N'-hydroxycarbamimidoyl)-2,6-dimethylphenethyl)piperidine-4-carboxylate
    参考文献:
    名称:
    New pyrazole derivatives
    摘要:
    本发明涉及式(I)的化合物,其制备过程,以及它们在治疗可通过sphingosine-1-phosphate受体(S1P1)激动剂改善的病理状况或疾病中的用途。
    公开号:
    EP2390252A1
  • 作为产物:
    描述:
    哌啶-4-甲酸乙酯3,5-dimethyl-4-(2-oxoethyl)benzonitrile溶剂黄146甲醇 、 sodium cyanoborohydride 作用下, 以 甲醇 为溶剂, 反应 0.5h, 以61%的产率得到ethyl 1-(4-cyano-2,6-dimethylphenethyl)piperidine-4-carboxylate
    参考文献:
    名称:
    [EN] PYRAZOLE DERIVATIVES AS S1P1 AGONISTS
    [FR] DÉRIVÉS DU PYRAZOLE EN TANT QU'AGONISTES S1P1
    摘要:
    本发明涉及式(I)的化合物,制备此类化合物的方法以及它们在治疗可通过鞘氨醇-1-磷酸受体(S1P1)激动剂改善的病理状况或疾病中的用途。
    公开号:
    WO2011144338A1
点击查看最新优质反应信息

文献信息

  • 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE
    申请人:Giulio Matassa Victor
    公开号:US20110311485A1
    公开(公告)日:2011-12-22
    The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.
    本公开涉及公式(I)的1,2,4-噁二唑衍生物,以及包含它们的药物组合物,以及它们作为S1P1受体激动剂在治疗中的使用。
  • [EN] 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE<br/>[FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE ET LEUR UTILISATION THÉRAPEUTIQUE
    申请人:ALMIRALL SA
    公开号:WO2010072352A1
    公开(公告)日:2010-07-01
    New derivatives of general formula (I), or pharmaceutically acceptable salts or N- oxides thereof wherein,either (i) A is selected from the group consisting of -N-, -O- and -S-; B and C are independently selected from the group consisting of -N- and -O-, with the proviso that two of A, B and C are nitrogen atoms, or (ii) two of A, B and C are -N- and one of A, B and C is -NH-; G1 is selected from the group consisting of -CH2-, -NH- and -O-; G2 is selected from the group consisting of -NR4- and -O-; R1 represents: > a 8 to 10 membered bicyclic N-containing heteroaryl group optionally substituted with a C1-4 carboxyalkyl group or a C1-4 aminoalkyl group, > a pyridyl group optionally substituted with one or more substituents selected from hydroxy groups, C1-4 alkyl groups, C1-4 carboxyalkyl groups, C1-4 haloalkyl groups, C1-4 alkoxy groups, amino groups, C1-4 aminoalkyl groups and C1-4 aminoalkoxy groups, > a pyridone group substituted with one or more C1-4 alkyl groups; C1-4 haloalkyl groups or C1-4 aminoalkyl groups, or > a group of formula:
  • [EN] PYRAZOLE DERIVATIVES AS S1P1 AGONISTS<br/>[FR] DÉRIVÉS DU PYRAZOLE EN TANT QU'AGONISTES S1P1
    申请人:ALMIRALL SA
    公开号:WO2011144338A1
    公开(公告)日:2011-11-24
    The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.
    本发明涉及式(I)的化合物,制备此类化合物的方法以及它们在治疗可通过鞘氨醇-1-磷酸受体(S1P1)激动剂改善的病理状况或疾病中的用途。
  • New pyrazole derivatives
    申请人:Almirall, S.A.
    公开号:EP2390252A1
    公开(公告)日:2011-11-30
    The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.
    本发明涉及式(I)的化合物,其制备过程,以及它们在治疗可通过sphingosine-1-phosphate受体(S1P1)激动剂改善的病理状况或疾病中的用途。
查看更多